ArticleJournal of virology2012
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response.Nature communications · 2025Article
- Virus-driven dysregulation of the BCR pathway: a potential mechanism for the high prevalence of HIV related B-cell lymphoma.Annals of hematology · 2024Review
- Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?Cell host & microbe · 2020Review
- CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.Oncoimmunology · 2020Article
- Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.PloS one · 2019Article
- The Role of BAFF System Molecules in Host Response to Pathogens.Clinical microbiology reviews · 2017Review
- Development of targeted adjuvants for HIV-1 vaccines.AIDS research and therapy · 2017Review
- Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies.The Journal of experimental medicine · 2017Article
- APRIL:TACI axis is dispensable for the immune response to rabies vaccination.Antiviral research · 2017Article
- Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer.Oncotarget · 2017Article
- Article
- Native-like Env trimers as a platform for HIV-1 vaccine design.Immunological reviews · 2017Review
- Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.Biomolecules · 2015Article
- HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.Science (New York, N.Y.) · 2015Article
- DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.Journal of virology · 2015Article
- Strategies to guide the antibody affinity maturation process.Current opinion in virology · 2015Review
- Immunosilencing a highly immunogenic protein trimerization domain.The Journal of biological chemistry · 2015Article
- Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.Current opinion in HIV and AIDS · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
Abstract
An HIV-1 vaccine remains elusive, in part because various factors limit the quantity and quality of the antibodies raised against the viral envelope glycoprotein complex (Env). We hypothesized that targeting Env vaccines directly to B cells, by fusing them to molecules that bind and activate these cells, would improve Env-specific antibody responses. Therefore, we fused trimeric Env gp140 to A PRoliferation-Inducing Ligand (APRIL), B-cell Activating Factor (BAFF), and CD40 Ligand (CD40L). The Env-APRIL, Env-BAFF, and Env-CD40L gp140 trimers all enhanced the expression of activation-induced cytidine deaminase (AID), the enzyme responsible for inducing somatic hypermutation, antibody affinity maturation, and antibody class switching. They also triggered IgM, IgG, and IgA secretion from human B cells in vitro. The Env-APRIL trimers induced higher anti-Env antibody responses in rabbits, including neutralizing antibodies against tier 1 viruses. The enhanced Env-specific responses were not associated with a general increase in total plasma antibody concentrations, indicating that the effect of APRIL was specific for Env. All the rabbit sera raised against gp140 trimers, irrespective of the presence of CD40L, BAFF, or APRIL, recognized trimeric Env efficiently, whereas sera raised against gp120 monomers did not. The levels of trimer-binding and virus-neutralizing antibodies were strongly correlated, suggesting that gp140 trimers are superior to gp120 monomers as immunogens. Targeting and activating B cells with a trimeric HIV-1 Env-APRIL fusion protein may therefore improve the induction of humoral immunity against HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.